Compare Enveric Biosciences Inc (ENVB) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Motorola Solutions Inc — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Motorola Solutions Inc trades at $443.51 (market cap $74.00B). The key difference: Motorola Solutions Inc is far larger — about 10882.4× Enveric Biosciences Inc's market cap, and Motorola Solutions Inc pays a 1.08% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Motorola Solutions Inc for 100 Days on average.
| ENVB | MSI | |
|---|---|---|
Market Cap | $6.80M | $74.00B |
Volume | 64,867 | 722,147 |
Sector | Health | Technology |
52-Week High | $10.80 | $491.24 |
52-Week Low | $1.27 | $363.83 |
Typical Hold Time | 14 Days | 100 Days |
Enterprise Value | -$1.49M | $82.90B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.48, down 1.0% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -235.48% and ROA at -193.53%, though it has beaten EPS expectations for four consecutive quarters. Recent developments include patent allowances for non-hallucinogenic therapeutics and positive preclinical data for EB-003.
While analyst consensus is 75% buy with no sell ratings, fundamental weaknesses in revenue generation and negative cash flow from operations pose significant risks. The stock's appeal hinges on clinical progress and regulatory milestones, making it suitable for risk-tolerant investors betting on biotech innovation amid high operational and financial volatility.
MSI trades at $444.18, down 0.96% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.41 surpassing the $3.85 estimate. Revenue growth has been steady, reaching $11.68 billion in 2025, and the firm recently announced a $2 billion share repurchase increase and a $139 million public safety contract in Louisiana.
The outlook remains positive with a consensus price target of $525.86, implying 18% upside, supported by a 70.59% buy rating from analysts. Risks include elevated valuation multiples, such as a P/E of 35.23, and significant investing cash outflows for acquisitions, which pressured net cash flow to -$937 million in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
